Skip to main content

Advertisement

Advertisement

commentary Commentary

Commentary: Manufacturing and distributing a COVID-19 vaccine could take years

Even if one of the 160 candidates is proven safe and effective, the biggest challenges in getting everyone vaccinated lie ahead, says an observer.

Commentary: Manufacturing and distributing a COVID-19 vaccine could take years

FILE PHOTO: A scientist prepares samples during the research and development of a vaccine against the coronavirus disease (COVID-19) at a laboratory of BIOCAD biotechnology company in Saint Petersburg, Russia June 11, 2020. REUTERS/Anton Vaganov/File Photo

SYDNEY: The world is hoping a safe and effective COVID-19 vaccine will soon become available. So far, more than 160 candidate vaccines are in development.

Some 31 of these have entered human clinical trials. One of them is Russia’s Sputnik V, which was granted approval by the country’s health ministry last week.

But the World Health Organisation (WHO) and a large number of international experts have urged Russia to conduct more testing to ensure the vaccine’s safety before using it.

Even if this candidate and others are proven to be safe and effective, developing the vaccine is just the first step. Some of the biggest challenges in getting everyone vaccinated still lie ahead.

LISTEN: The COVID-19 vaccine will be the biggest product launch in history. Can we pull it off?

READ: Commentary: COVID-19 vaccine – why is it taking so long to develop one?

MANUFACTURING THE VACCINE

The first major challenge after a vaccine is developed is to produce enough of it to start vaccination programmes. One estimate puts global vaccine production capacity at up to 6.4 billion doses per year, though this is based on single-dose influenza vaccines.

But some of the COVID-19 vaccines currently in development require two or three injections. This means, if the same technology for COVID-19 vaccines is required as for influenza vaccines, global production is severely reduced.

It has been estimated that to achieve sufficient levels of immunity among the global population with a two-dose vaccine, we would need between 12 billion and 15 billion doses – roughly twice the world’s current total vaccine manufacturing capacity.

Shifting to exclusively manufacture a COVID-19 vaccine will also mean shortages of other vaccines such as those for preventable childhood diseases such as measles, mumps and rubella. So prioritising COVID-19 could cost many other lives.

READ: Commentary: Booster shots will likely be needed even if a COVID-19 vaccine is ready

BUYING VACCINES IN ADVANCE

Given these production constraints, governments have previously tended to sign advance purchase agreements with vaccine manufacturers to guarantee access. These commercial-in-confidence agreements are usually signed in secret, often with different prices being charged to different governments depending on whether they are the first customer or 30th and their ability to pay.

File photo of an employee of German biopharmaceutical company CureVac, demonstrating research on a vaccine for COVID-19 at a laboratory in Tuebingen, Germany, Mar 12, 2020. (Photo: REUTERS/Andreas Gebert) FILE PHOTO: An employee of German biopharmaceutical company CureVac, demonstrates research on a vaccine for the coronavirus (COVID-19) disease at a laboratory in Tuebingen, Germany, March 12, 2020. REUTERS/Andreas Gebert/File Photo

It also means countries that can afford to buy vaccine stocks in advance get first access, leaving poorer nations to miss out or be forced to wait years. This has happened on at least two previous occasions.

In 2007, Indonesia found it couldn’t purchase H5N1 influenza (bird flu) vaccines despite being one of the worst-affected countries at the time. This was because several other richer countries had already organised advanced purchase agreements, and led Indonesia to temporarily withhold sharing virus samples with the WHO in retaliation

And in 2009, rich nations bought up almost all the stock of H1N1 influenza vaccines, crowding out less-developed nations.

LISTEN: Recovery, restructuring and possibly rebound? The outlook for the Singapore economy

READ: Commentary: As world waits for coronavirus vaccine, antibodies treatment a needed plan B

Most of the world’s leaders have stated that a successful COVID-19 vaccine should be shared equitably. The COVAX initiative launched by the WHO, global vaccine alliance GAVI, and the Coalition for Epidemic Preparedness Innovations, aims to deliver 2 billion doses of a COVID-19 vaccine by the end of 2021.

Countries representing 60 per cent of the world’s population have signed up to this initiative, but not everyone has and we’ve already seen a number of instances in which governments have sought to gain priority access over others.

The problem with this vaccine nationalism is that rather than being based on equity or need, it will create global supply problems with those countries that have special deals getting access to the vaccine first.

READ: WHO calls for end to COVID-19 'vaccine nationalism'

DISTRIBUTING THE VACCINE

The second key challenge is distributing the COVID-19 vaccine. Most vaccines need to be transported in cold storage, which presents a problem for many parts of the world where electricity failure is a common feature of daily life.

The WHO has estimated up to 50 per cent of vaccines are wasted every year, often because of inadequate temperature control in supply chains.

A health worker shows unused packs of anti-dengue vaccine Dengvaxia before returning it inside a freezer for storage at the Manila Health Department, Dec 5, 2017. (Photo: Reuters/Romeo Ranoco)

With the marked reduction in international passenger air travel, the movement of cargo has also slowed. This will need to be addressed with airlines ahead of any attempts to distribute the vaccine.

Beyond the initial transport from the manufacturer, getting the vaccine to rural and remote communities requires sophisticated logistical services, which many poorer countries lack.

Without substantial investment to strengthen international and national supply chains, it will be years before vaccines can reach everyone who needs them.

READ: When can you get a COVID-19 vaccine? Five things you should know

READ: Commentary: How ‘good’ does a COVID-19 vaccine need to be to stop the pandemic?

While some might argue more needs to be done to secure a COVID-19 vaccine, it’s not necessarily the best move to enter into advanced purchase agreements. They are expensive, and there’s no guarantee the candidates will be safe and effective.

Nevertheless, avoiding putting all eggs in one basket and supporting multiple vaccine initiatives is sensible strategy. 

It’s also good to see governments supporting initiatives such as COVAX that aim to make the vaccine available to those countries with limited means to pay. While some may see this as excessive altruism, it’s in the broader interest, given borders are likely to remain closed until a vaccine has been made widely available. The quicker the world is vaccinated, the sooner borders can be reopened.

What this means for the average person is that we should get ready for a long wait. Even with an advanced purchase agreement to secure priority access to a safe and effective COVID vaccine, initial supplies are going to be extremely limited.

Priority groups like frontline healthcare workers will get first access, followed by those who are more vulnerable to serious illness. If you’re otherwise fit and healthy, you should be prepared that it could take up to a few years after vaccines become available.

If they become available sooner, it will only be because countries have agreed to work together like never before. Let’s hope they can do it.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the COVID-19 outbreak: https://cna.asia/telegram

Adam Kamradt-Scott is Associate Professor at the Centre for International Security Studies, University of Sydney. This commentary first appeared on The Conversation.

Source: CNA/el

Advertisement

Also worth reading

Advertisement